Grant: Master's Award: Canada Graduate Scholarships
University of Ottawa
$17,500.00
Pancreatic Cancer treatment using oncolytic virus based therapies
EF 2023-24
Résumé
Pancreatic cancer is a deadly disease with a low survival rate, and current treatments such as surgery, chemotherapy, and radiation have limited effectiveness. The KRAS oncogene is a common culprit in pancreatic cancer, mutated in over 90% of pancreatic cancers, but targeting it has been challenging. Recent advances in RNA interference (RNAi) technology, focusing on KRAS, show promise. However, a common limitation of this technology is its inability to infiltrate the tumour cells. To overcome this challenge, my project aims to use oncolytic viruses (OVs) to deliver RNAi targeting both mutated KRAS and PD-L1, which are key players in the cancer's immunosuppressive microenvironment. The idea is that using an OV as a delivery platform will facilitate oncolysis while downregulation of KRAS and/or PD-L1 will lead to immune-mediated cell death.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
506347
Name
Rathod Khushi
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Pancreatic Cancer treatment using oncolytic virus based therapies
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Exosomes; Immunotherapies; Kras; Oncolytic Viruses; Pancreatic Cancer; Pd-L1; Solid Tumours; Tumor Microenvironment; Vesicular Stomatitis Virus
Abstract
Pancreatic cancer is a deadly disease with a low survival rate, and current treatments such as surgery, chemotherapy, and radiation have limited effectiveness. The KRAS oncogene is a common culprit in pancreatic cancer, mutated in over 90% of pancreatic cancers, but targeting it has been challenging. Recent advances in RNA interference (RNAi) technology, focusing on KRAS, show promise. However, a common limitation of this technology is its inability to infiltrate the tumour cells. To overcome this challenge, my project aims to use oncolytic viruses (OVs) to deliver RNAi targeting both mutated KRAS and PD-L1, which are key players in the cancer's immunosuppressive microenvironment. The idea is that using an OV as a delivery platform will facilitate oncolysis while downregulation of KRAS and/or PD-L1 will lead to immune-mediated cell death.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Rathod, Khushi
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~